UAB

University of Alabama at Birmingham (UAB) Health System and Humana Sign Agreement, Expanding Humana’s Medicare Advantage Provider Network in Alabama

Retrieved on: 
måndag, juni 3, 2024
Men, General Health, Professional Services, Family, Optical, Consumer, Hospitals, Health Insurance, Surgery, Insurance, Women, Seniors, Health, Medicare, Health system, University, Multimedia, UAB, Patient, Health insurance

The University of Alabama at Birmingham (UAB) Health System and Humana , a leading health and well-being company, have signed an in-network agreement, expanding access to care for all Humana Medicare Advantage members in Alabama.

Key Points: 
  • The University of Alabama at Birmingham (UAB) Health System and Humana , a leading health and well-being company, have signed an in-network agreement, expanding access to care for all Humana Medicare Advantage members in Alabama.
  • View the full release here: https://www.businesswire.com/news/home/20240603751242/en/
    The University of Alabama at Birmingham (UAB) Health System and Humana, a leading health and well-being company, have signed an in-network agreement, expanding access to care for all Humana Medicare Advantage members in Alabama.
  • (Photo: Business Wire)
    Humana’s Medicare Advantage members in Alabama now have in-network access to the following UAB and UAB-affiliated facilities:
    “UAB is well-respected and well-known for providing quality healthcare to its patients,” said Matt Berger, President of Humana’s Gulf South Region.
  • “We are pleased to be able to offer all of our Humana Medicare Advantage members in Alabama an additional option for high quality healthcare as we help our members achieve and maintain their best health.”
    The agreement took effect earlier this year.

Sherlock Biosciences Starts Clinical Trial of Disposable Molecular STI Test vs. Central Lab Tests

Retrieved on: 
torsdag, maj 30, 2024
Health, Infectious Diseases, Genetics, Other Health, General Health, Clinical Trials, Biotechnology, DNA, STI, UAB, Neisseria gonorrhoeae, Sherlock Biosciences, Privacy, Chlamydia trachomatis, University, CLIA, Population health, OTC, Birmingham School of Law, RNA, Public health, PCR

Sherlock Biosciences today announced the enrollment of the first participant in the PROMISE Study, a multicenter clinical study to evaluate the performance of the Sherlock STI over-the-counter (OTC) disposable molecular test against the gold standard of central lab PCR testing.

Key Points: 
  • Sherlock Biosciences today announced the enrollment of the first participant in the PROMISE Study, a multicenter clinical study to evaluate the performance of the Sherlock STI over-the-counter (OTC) disposable molecular test against the gold standard of central lab PCR testing.
  • The Sherlock test is one of the first molecular disposable tests for Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG).
  • Test results are provided in under 30 minutes by analyzing DNA and RNA self-collected through penile meatal or vaginal swabs.
  • “Enrollment of the first participant in this clinical trial marks a major milestone for Sherlock and for population health.

Lithuanian Biotech Pioneer 'Nando' Embarks on Global Expansion With New Management Team and Innovative Production Line

Retrieved on: 
tisdag, maj 7, 2024
Agriculture, Fertilizer, Livestock, UAB, Fine chemical

KAUNAS, LITHUANIA, May 7, 2024 - (ACN Newswire) - In a strategic enhancement of its management team, "Nando" welcomes four seasoned professionals, each bringing a wealth of experience from reputable organizations.

Key Points: 
  • KAUNAS, LITHUANIA, May 7, 2024 - (ACN Newswire) - In a strategic enhancement of its management team, "Nando" welcomes four seasoned professionals, each bringing a wealth of experience from reputable organizations.
  • This investment boosts production volume, enhances productivity, and ensures competitive pricing to meet the escalating market demand.
  • Justinas Taruska, CEO of "Nando", stated, "Our main goal is to feature a highly automated biotechnological production line.
  • The new production line is renowned for its unique microorganism purification technology, a rarity in the entire Baltic region.

Foundation for Sarcoidosis Research and Walgreens Unite in Alabama to Boost Sarcoidosis Awareness and Spring Vaccine Education for April Awareness Month

Retrieved on: 
måndag, april 15, 2024
Education, Sarcoidosis, University, Inflammation, Pharmacy, Hospital, Blood, Respiratory syncytial virus, Death, Partnership, Research, Vaccine, Medicine, Bronchiolitis, Disease, Conditional sentence, Nervous system, University of Alabama, Patient, Immunodeficiency, UAB, Caregiver, Lung, Diagnosis, Infection, RSV, FSR, Pharmaceutical industry

CHICAGO, April 15, 2024 (GLOBE NEWSWIRE) -- Beginning April 15th, Walgreens, a pharmacy and retail leader who plays a critical role in the U.S. healthcare system by providing a wide range of pharmacy and healthcare services, including those that drive equitable access to care for the nation’s medically underserved populations, and Foundation for Sarcoidosis Research (FSR), the leading international sarcoidosis organization, are proud to announce its renewed partnership to raise education and awareness about sarcoidosis and the importance of spring vaccinations with all Alabama-based Walgreens stores. As part of April’s Sarcoidosis Awareness Month from now through April 30th, all Walgreens stores in Alabama will join forces with FSR in an effort to spread awareness and support those affected by this chronic disease.

Key Points: 
  • As part of April’s Sarcoidosis Awareness Month from now through April 30th, all Walgreens stores in Alabama will join forces with FSR in an effort to spread awareness and support those affected by this chronic disease.
  • During this awareness campaign, Walgreens stores across Alabama will provide informational resources about sarcoidosis to their customers.
  • Every donation will directly support FSR’s initiatives to accelerate sarcoidosis research and provide crucial support to patients and their families.
  • FSR is proud to partner with Walgreens to raise awareness of the spring respiratory vaccines, which include RSV and Pneumonia.

Popular ArthritisPower® Patient Registry Expands Conditions and Becomes PatientSpot™

Retrieved on: 
måndag, april 15, 2024
Technology, FDA, Managed Care, Health, General Health, Health Technology, Medical Devices, Research, Apps, Applications, Artificial Intelligence, Science, Conditional sentence, Education, University, Patient, Psoriatic arthritis, Food, Spondyloarthropathy, Partnership, Human, Habit, Intelligence, Entrepreneurship, Arthritis, MPH, Rheumatoid arthritis, Medicine, UAB, Movement, RMD, Nursing

Patients can now join the registry and its community with any chronic condition they wish to share, establishing it as a truly disease-agnostic platform.

Key Points: 
  • Patients can now join the registry and its community with any chronic condition they wish to share, establishing it as a truly disease-agnostic platform.
  • Erik Stone, MA, Associate Director, Learning Experience Design at GHLF, explained, “Many of the patients we assist navigate multiple chronic conditions alongside arthritis.
  • It emerged as an innovative nationwide research registry, focusing on patients with rheumatic and musculoskeletal conditions (RMD), including rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis.
  • “We treasure the insights and experiences shared by patients dealing with arthritis and related conditions.

Digital Lending Market size to record USD 19.14 billion growth from 2023-2027, Rise in adoption of cloud-based digital lending servicing software offerings is one of the key market trends, Technavio

Retrieved on: 
fredag, april 19, 2024
Cloud, USD, MSME, Intercontinental Exchange, Intellect, Big data, Nucleus Software Exports, Internet, Blockchain, Abrigo, CoreLogic, Machine learning, First American Corporation, Artificial intelligence, CAPEX, Financial institution, Digital, Automation, App Store (iOS/iPadOS), Privacy, Computer security, UAB, Fiserv, Telecom, Organization, Growth, Temenos AG, OPEX

The digital lending market is experiencing rapid growth due to cloud-based loan servicing.

Key Points: 
  • The digital lending market is experiencing rapid growth due to cloud-based loan servicing.
  • In the rapidly evolving digital lending market, financial security is a top priority.
  • In the Digital Lending Market, financial institutions leverage technology to process loan applications, assess creditworthiness, and disburse loans digitally.
  • Digital Lending Market  is fragmented ; the companies are competing with competitors and are trying to get greater market share.

Acclaimed Clinical Geneticist Dr. Bruce Korf Honored with 2024 David L. Rimoin Lifetime Achievement Award in Medical Genetics from the ACMG Foundation for Genetic and Genomic Medicine

Retrieved on: 
onsdag, mars 13, 2024
Department of Defence, Friends, Patient, Medical genetics, Travel, Child, Neurofibromatosis, Practice, UAB, Gene expression, Dean (education), Education, Rockefeller University, Seed, NF, NIH, American College, Pediatrics, Person, Karyotype, MD–PhD, Boston Children's Hospital, Principle, Birmingham School of Law, Neurology, FACOG, Genetics, Cornell University, American Journal, Research, Hospital, University, Human genetics, Student, Publication, DRS, ACMG, Book, Genetic distance, DSM-IV codes, Diagnosis, FACMG, Empathy, Montefiore Medical Center, Distinguishing, Mouse, Hope, Doctor of Philosophy, Life, Genetic, Bangladesh Technical Education Board, Physician, Nursing

BETHESDA, Md., March 13, 2024 /PRNewswire/ -- Renowned clinical geneticist Bruce Korf, MD, PhD, FACMG, has been named the recipient of the 2024 ACMG Foundation for Genetic and Genomic Medicine's David L. Rimoin Lifetime Achievement Award in Medical Genetics.

Key Points: 
  • BETHESDA, Md., March 13, 2024 /PRNewswire/ -- Renowned clinical geneticist Bruce Korf, MD, PhD, FACMG, has been named the recipient of the 2024 ACMG Foundation for Genetic and Genomic Medicine's David L. Rimoin Lifetime Achievement Award in Medical Genetics.
  • Dr. Korf is an authentic, kind and ethical human being whose life and career in medical genetics are unparalleled."
  • "Dr. Korf's extraordinary accomplishments in clinical genetics, neurofibromatosis, and genomics, as well as his dedication to education make him a well deserving winner of the David Rimoin Lifetime Achievement Award.
  • Before he died, David appreciated the opportunity to work with Bruce first-hand in the editing of Principles and Practice of Medical Genetics as well as on numerous committees for the ACMG.

DC BLOX Expands Birmingham Data Center to Empower High-Performance Computing

Retrieved on: 
torsdag, mars 7, 2024
Commercial Building & Real Estate, Apps, Applications, Technology, Construction & Property, Software, Networks, Hardware, Data Management, Artificial Intelligence, HPC, AVP, Research, Biotechnology, Testament, Artificial intelligence, University, Government, Economic development, COVID-19, GPU, Machine learning, UAB, Heart, Graphics processing unit, Renewable energy

DC BLOX , a premier provider of secure and reliable data centers and fiber network solutions throughout the Southeast, today announced the completed expansion of its Birmingham, Alabama data center .

Key Points: 
  • DC BLOX , a premier provider of secure and reliable data centers and fiber network solutions throughout the Southeast, today announced the completed expansion of its Birmingham, Alabama data center .
  • The new data hall design signifies a major advancement in DC BLOX’s mission to deliver cutting-edge solutions that empower local businesses, government entities, and academic institutions.
  • “This expansion underscores DC BLOX’s steadfast dedication to empowering the technology-based economy of Birmingham and beyond,” said Jeff Uphues, CEO of DC BLOX .
  • For more information on DC BLOX and our expanded Birmingham data hall, please visit https://www.dcblox.com .

ANEW MEDICAL ANNOUNCES KEY PATENT ISSUED IN CHINA TO PROTECT KLOTHO PROTEIN AND GENE DELIVERY SYSTEMS

Retrieved on: 
måndag, mars 4, 2024
CFO, Acquisition, Ageing, ICREA, LEAS, Memory, Patent, Cognition, UAB

NEW YORK, March 4, 2024 /PRNewswire/ -- ANEW MEDICAL, INC. ("ANEW" or "the Company") (OTCPK: LEAS) a US-based biotechnology company ("ANEW") focused on developing cell and gene- based treatments to affect aging and age-related diseases, announced that is has been granted and issued a patent in China, number CN 117126829 A for the use of ANEW's Klotho protein and Klotho gene delivery and expression systems in the treatment of cognition, memory and neurodegenerative diseases.

Key Points: 
  • NEW YORK, March 4, 2024 /PRNewswire/ -- ANEW MEDICAL, INC. ("ANEW" or "the Company") (OTCPK: LEAS) a US-based biotechnology company ("ANEW") focused on developing cell and gene- based treatments to affect aging and age-related diseases, announced that is has been granted and issued a patent in China, number CN 117126829 A for the use of ANEW's Klotho protein and Klotho gene delivery and expression systems in the treatment of cognition, memory and neurodegenerative diseases.
  • Dr. Joseph Sinkule, the Founder and CEO of ANEW stated "Obtaining a patent in China was difficult but important to our global product development programs in neurodegenerative diseases.
  • The aging population in China is affected by the same age-related diseases we are fighting in the US and Europe.
  • In May 2023, ANEW announced its proposed merger with a special purpose acquisition company ("SPAC") called Redwoods (NASDAQ: RWOD) ("RWOD" or "Redwoods").

Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board

Retrieved on: 
måndag, januari 8, 2024
Oncology, Health, Stem Cells, Neurology, Research, Science, Biotechnology, Virus, Cell, Cancer, Distinguishing, University, Biologic, Dove Medical Press, Neuroscience, UAB Hospital, Emory University, National academy, UAB, Glioblastoma, Radiation therapy, Neuro, Nature Biotechnology, Physician, Birmingham School of Law, Engineering, Neurosurgery, Potyvirus, Harvard Medical School, Supernova, Pulmonology, Hospital, Bangladesh Technical Education Board, University of Groningen, PNAS, Pharmaceutical industry

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies today announced the appointment of three new members to its Scientific and Medical Advisory Board.

Key Points: 
  • Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies today announced the appointment of three new members to its Scientific and Medical Advisory Board.
  • “Calidi continues to expand our Scientific and Medical Advisory Board, adding leading physicians and scientists from the top cancer hospitals and research institutions in the United States,” said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics.
  • Dr. Chiocca is a faculty member at Harvard Medical School and leads a laboratory focused on developing novel genetic therapies for malignant brain tumors.
  • from the University of Tennessee and completed his residency and fellowship at UAB Hospital in Neurology and Neuro-oncology.